Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment.
Kelly M Winter, Lacey Johnson, Matthew Kwok, Diana Vidovic, Ryan A Hyland, Nina Mufti, Anna Erickson, Denese C Marks
Index: Transfusion 54(7) , 1798-807, (2014)
Full Text: HTML
Abstract
Over the past decade there has been a growth in the development of pathogen reduction technologies to protect the blood supply from emerging pathogens. This development has proven to be difficult for red blood cells (RBCs). However the S-303 system has been shown to effectively inactivate a broad spectrum of pathogens, while maintaining RBC quality.A paired three-arm study was performed to compare the in vitro quality of S-303-treated RBCs with RBCs stored at room temperature (RT) for the duration of the treatment (18-20 hr) and control RBCs stored at 2 to 6°C. Products were sampled weekly over 42 days of storage (n = 10) and tested using an array of in vitro assays to measure quality, metabolism, and functional variables.During S-303 treatment there was a slight loss of RBCs and hemoglobin (Hb < 5 g). Hemolysis, glucose consumption, and potassium release were similar in all groups during the 42 days of storage. S-303-treated RBCs had a significantly lower lactate concentration and pH compared to the paired controls. The S-303-treated RBCs had significantly higher adenosine triphosphate than the RT and control RBCs. There was a significant loss of 2,3-diphosphoglycerate in the S-303-treated products, which was also observed in the RT RBCs. Flow cytometry analysis demonstrated similar RBC size, morphology, expression of CD47, and glycophorin A in all groups.RBCs treated with S-303 for pathogen reduction had similar in vitro properties to the paired controls and were within transfusion guidelines.© 2014 Australian Red Cross Blood Service. Transfusion © 2014 AABB.
Related Compounds
Related Articles:
2014-06-05
[Int. J. Pharm. 467(1-2) , 90-9, (2014)]
2015-04-30
[Int. J. Pharm. 484(1-2) , 283-91, (2015)]
Study on the phase I metabolism of novel synthetic cannabinoids, APICA and its fluorinated analogue.
2015-02-01
[Drug Test. Anal. 7(2) , 131-42, (2015)]
An antifungal mechanism of curcumin lies in membrane-targeted action within Candida albicans.
2014-11-01
[IUBMB Life 66(11) , 780-5, (2015)]
2015-01-30
[J. Chromatogr. A. 1379 , 74-82, (2015)]